At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 13 enrolled
Drug / intervention
prucalopride +1 moredrug
Likely dose
prucalopride 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Randomized, Crossover, Reader-blinded Study to Investigate the Effect of Prucalopride and Polyethylene Glycol 3350 on Colon Motility With Intramural Manometry in Subjects With Chronic Constipation
In Brief
A Phase 4 clinical trial evaluating prucalopride and PEG 3350 for Chronic Constipation. Completed, enrolled 13 participants across 3 sites in 3 countries.
Detailed Summary
To evaluate the different effects of prucalopride and PEG 3350 + electrolytes on colon motor activity in subjects that are chronically constipated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Constipation
CountriesBelgium, United Kingdom, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 2012
Enrollment StartFeb 2013
Primary CompletionNov 2013
TodayJul 2026
First PostedOct 16, 2012
Enrollment StartFeb 27, 2013
Primary CompletionNov 27, 2013
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 13.7 years ago
Interventions
prucalopridedrug
One 2 mg tablet orally administered on Day 1
PEG 3350drug
13.8g polyethylene glycol (PEG) 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water. Administered twice orally on Day 1(once in the morning and once prior to lunch).